摘要
目的 评价泰素联合卡铂化疗和同步放疗在局部晚期非小细胞肺癌治疗中的疗效和毒性反应。方法 自 1996年 7月至 1998年 6月 ,15例不能手术的初治局部晚期非小细胞肺癌患者行泰素联合卡铂化疗和同步放疗。ⅢA期 7例 (47% ) ,ⅢB期 8例 (5 3% ) ;鳞癌 14例 (93 % ) ,腺癌 1例 (7% )。在放疗开始的第 1天、第 15天和第 2 9天分别给予泰素 40mg/m2 (静滴 1小时 )和卡铂 15 0mg/m2 ,放疗总剂量为 6 0～ 6 5Gy/30～ 33次 /6～ 7周。结果 放疗结束后 2个月进行疗效评价。总有效率为 73 % (11/15 ) ,其中完全缓解 (CR) 2例 ,部分缓解 (PR) 9例。主要毒性反应是放射性食管炎和白细胞减少。Ⅱ度放射性食管炎 6例 ;白细胞减少Ⅱ度 2例 ,Ⅲ度 1例。 1年生存率为 5 3 .3 % (8/15 )。结论 泰素联合卡铂化疗和同步放疗对局部晚期非小细胞肺癌是一种有希望的治疗 ,有效率较高 ,毒性反应可接受。但需进一步总结远期生存率 。
Objective Based on superior results with combinedmodality therapy in patients with advanced, unresectable nonsmall cell lung cancer (NSCLC), to evaluate the activity and toxicity of combination of paclitaxel with carboplatin and concurrent radiation therapy. Methods Fifteen previously untreated patients with inoperable locally advanced NSCLC (7 with stage ⅢA and 8 with ⅢB; 14 with squamous and 1 with adenocarcinoma) were entered into this study from July, 1996 to June, 1998. Patients received paclitaxel 40?mg/m2 over 1 hour and carboplatin 150?mg/m2, in day 1, 15, 29 during the radiation therapy of 60～65?Gy in 30～33 fractions during 6～7 weeks. Results The response was evaluated two months after radiotherapy. Two patients achieved a complete response (CR) (13%), and 9 patients (60%) achieved a partial response (PR), for an overall response rate of 73%. Three patients had stable disease, and one patient progressed during the therapy. 1year overall survival rate was 53.3%(8/15). Esophagitis and leukopenia were the principal toxicity. Grade 2 esophagitis occurred in 6 patients (40%), grade 2 and 3 leukopenia in 2 patients (13.3%) and 1 patient (6.7%) respectively. Conclusion Combined modality therapy with paclitaxel, carboplatin chemotherapy and concurrent radiation is a promising treatment for locally advanced NSCLC, which has a high response rate and acceptable toxicity. A randomized trial will be necessary to further evaluate the usefulness of these findings.
出处
《中国肺癌杂志》
CAS
2000年第5期333-335,共3页
Chinese Journal of Lung Cancer
关键词
非小细胞肺癌
泰素
卡铂
同步放化疗
Non-small cell lung cancer
Paclitaxel
Carboplatin
Concurrent chemoradiotherapy
